UpToDate’s Post

View organization page for UpToDate, graphic

115,198 followers

Pyruvate kinase (PK) deficiency is a red blood cell enzyme disorder that causes chronic hemolysis. The PK activator mitapivat was approved in 2022 for people with anemia from PK deficiency based on improvements in hemoglobin over 24 weeks. Now, with follow-up of 96 weeks, mitapivat has demonstrated reductions in iron overload. This supports using mitapivat for PK deficiency. Although not approved in individuals <18 years, we use it in younger patients after discussion of risks and benefits. Discover What's New in #hematology: https://ow.ly/SrzE50SvxL1 #ClinicalUpdates #meded

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics